
Everyone hates wasps. But this scientist wants us to love them.
Hatred of wasps goes back thousands of years — Aristotle denigrated them as 'devoid of the extraordinary features' which bees possess. But Seirian Sumner, professor of behavioral ecology at University College London (UCL), wants to show there's more to wasps than meets the eye. She has devoted her career as a zoologist to studying the insects; she has written a book on them, and even her Instagram handle is 'waspprof.'
She was involved in the recently opened World of Wasps exhibition at the UCL Grant Museum of Zoology in London, which hopes to 'reveal the unseen lives of wasps.' Speaking to CNN from the exhibition, Sumner gave her top five reasons why we should all love wasps as much as she does.
Pest control
'Wasps are nature's pest controllers. A world without wasps would mean that we would be inclined to use more chemicals to control the populations of the other insects and creepy crawlies that we don't like: caterpillars, aphids, spiders, beetles – you name it – there is a wasp that hunts it. So wasps are really important top predators in regulating all of those insect populations within the ecosystem.'
Pollination
'Bees sting and yet we tolerate that because we know what they do. We understand that they're important in ecosystems as pollinators. Wasps are equally important.
'Just like bees, they visit flowers to get nectar. Although they hunt, the prey is for their offspring, it's not for the adults themselves. They need to get some nutrition from somewhere, and they get that from flowers through nectar, just like bees do.'
Medicines
'Some (wasp) venom may potentially be a cure for cancer. (Indeed, one study has shown that a Brazilian wasp can kill cancer cells without harming surrounding healthy cells.)
Wasps also have lots of antibiotic in their venom and on their bodies that they use to keep their prey disease free. We should start tapping into the microbial defences that wasps have.'
Food
'Wasps are a popular source of nutrition for humans around the world. Particularly in Asia, people love to eat wasps. They will boil up the larvae or freeze dry the pupae, mix it with a bit of chili – nothing is better. They're really high in protein, low in fat and there are even people in parts of the world who actively farm wasps in order to produce enough of these juicy, amazing larvae to eat because they're such an important source of food.'
Paper makers
'They are supreme paper makers, and there is the idea that we got the idea of how to make paper by watching wasps.
'Most people have seen a wasp collecting a little bit of bark from a tree stump or a fence post. They mix it up with their saliva and smooth it out into this beautiful, thin paper that they then use to construct these huge football-sized societies that they live within.
The paper inside these nests is truly remarkable. There are three different types. On the outside, you've got this envelope which is quick and dirty for them to build. Inside you've got the combs that are strong but light, like the layers inside a high-rise building. The combs are then strutted together with a third type of paper, which is really strong and squidgy. If you try and pull it apart with your hands, you simply can't do it. All of that just inside a single wasp nest.'
Bonus point: A model society
'(The polistes paper wasp) is like the insect version of a meerkat. Unlike the yellowjacket wasps and the honeybees, where (individuals) are committed during development to become a queen or a worker, these guys, when they hatch as adults, the whole world is their oyster.
'They can be a queen, they can be a worker, they can start life as a worker and switch to be a queen. That's just like a meerkat society where you have breeders and then you have non-breeders who will be looking out for predators or go out foraging. Everyone is helping together, and this is exactly what these (wasps) do.
'They help us understand the evolution of altruism, why any individual should give up its chance to reproduce in order to help another reproduce. These wasps have been really important in understanding why animals come together to live in groups.'
The World of Wasps exhibition at the UCL Grant Museum of Zoology in London runs until January 24, 2026.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
ADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025
LAUSANNE, Switzerland, Aug. 5, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Tuesday, August 12, 2025, at 8:30 a.m. EDT to report financial results for the second quarter of 2025 and provide operational updates. To access the conference call, please register here. The participant toll-free dial-in number is 1-800-836-8184 for North America and Canada. It is recommended that you join 10 minutes before the event, though you may pre-register at any time. A live webcast of the call will be available under "Events and Presentations" in the Investors section of the ADC Therapeutics website at The archived webcast will be available for 30 days following the call. About ADC Therapeutics ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA and a PSMA-targeting ADC. ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics is leveraging its expertise to advance IND-enabling activities for a next-generation PSMA-targeting ADC which utilizes a differentiated exatecan-based payload with a novel hydrophilic linker. Headquartered in Lausanne (Biopôle), Switzerland, with operations in London and New Jersey, ADC Therapeutics is focused on driving innovation in ADC development with specialized capabilities from clinical to manufacturing and commercialization. Learn more at and follow us on LinkedIn. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify forward-looking statements by terminology such as "may", "will", "should", "would", "expect", "intend", "plan", "anticipate", "believe", "estimate", "predict", "potential", "seem", "seek", "future", "continue", or "appear" or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the success of the Company's strategic restructuring plan; changes in estimated costs associated with the restructuring plan including the workforce reduction and planned closure of the UK facility; the expected cash runway into 2028 which assumes use of minimum liquidity amount required to be maintained under its loan agreement covenants; whether future LOTIS-7 clinical trial results will be consistent with or different from the LOTIS-7 data presented at EHA and ICML and future compendia and regulatory strategy and opportunity; the timing of the PFS events for LOTIS-5 and the results of the trial and full FDA approval; the Company's ability to grow ZYNLONTA® revenue in the United States and potential peak revenue; the ability of our partners to commercialize ZYNLONTA® in foreign markets, the timing and amount of future revenue and payments to us from such partnerships and their ability to obtain regulatory approval for ZYNLONTA® in foreign jurisdictions; the timing and results of the Company's or its partners' research and development projects or clinical trials including LOTIS 5 and 7, as well as early pre-clinical research for our exatecan-based ADC targeting PSMA; the timing and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company's products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company's indebtedness, including Healthcare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company's activities by such indebtedness, the ability to comply with the terms of the various agreements and repay such indebtedness and the significant cash required to service such indebtedness; and the Company's ability to obtain financial and other resources for its research, development, clinical, and commercial activities. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K and in the Company's other periodic and current reports and filings with the U.S. Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. CONTACTS:Investors and MediaNicole RileyADC 862-926-9040 View original content to download multimedia: SOURCE ADC Therapeutics SA Sign in to access your portfolio
Yahoo
6 hours ago
- Yahoo
Experiment Recreates The Universe's Very First Chemical Reactions
The first chemical reactions in the wake of the Big Bang have been recreated for the first time in conditions similar to those in the baby Universe. A team of physicists Led by Florian Grussie of the Max Planck Institute for Nuclear Physics (MPIK) in Germany has reproduced the reactions of helium hydride ion (HeH+), a molecule made from a neutral helium atom fusing with an ionized atom of hydrogen. These are the first steps that lead to the formation of molecular hydrogen (H2); the most abundant molecule in the Universe and the stuff from which stars are born. The new work, therefore, elucidates some of the earliest processes that gave rise to the Universe as we know it today. Related: The First Molecular Bond in The Universe Has Finally Been Detected in Space The birth throes of the Universe some 13.8 billion years ago produced a hot, dense soup of fundamental particles simmering at temperatures too high for atoms to form. It took about 380,000 years for nuclei and electrons to lose enough energy to congeal into the very first elements. Those elements were the lightest the periodic table has to offer; about 75 percent hydrogen, 25 percent helium, and trace amounts of lithium. Hydrogen continues to dominate the Universe's ingredient list today, as clouds of molecular gas that give birth to the stellar furnaces from which the heavier elements are born, either through fusion or violent explosions. None of that, however, could happen without HeH+ – a molecule that scientists believe played a huge role in cooling the Universe enough so that the molecular clouds could contract enough to attain the density required to collapse under their own gravity to form the seeds of baby stars. That's because HeH+ has a comparatively large separation between its positive and negative charges. In the presence of an electric field, a molecule with a large charge separation undergoes an energy shift that helps dissipate heat, which means HeH+ theoretically played a key role in paving the way for the formation of the first stars. The researchers performed their experiments at the Max Planck Institute's Cryogenic Storage Ring, a facility designed to perform experiments in a vacuum environment at temperatures just a few degrees above absolute zero, around -267 degrees Celsius (-449 Fahrenheit), mimicking the conditions of deep space. There, they carefully studied interactions between HeH+ and a hydrogen atom with one extra neutron in its nucleus, known as deuterium. An interaction between HeH+ and deuterium generates a neutral helium atom and a molecule consisting of one neutral hydrogen atom and one charged deuterium atom (HD+), with lower energy levels than the original components. Within the storage ring, the researchers fired two beams of particles; one with HeH+ molecules, the other with neutral deuterium. They changed the speed of the two beams to alter the energy at which the particles collided as a proxy for temperature to see if temperature played a role in the reaction rate. It did not. The rate at which the reaction took place remained steady, regardless of the proxy temperature – suggesting that the role HeH+ played in the early Universe did not decline as cooling unfolded, and that its role in the formation of the first generation of stars was a significant one. "Previous theories predicted a significant decrease in the reaction probability at low temperatures, but we were unable to verify this in either the experiment or new theoretical calculations by our colleagues," physicist Holger Kreckel from the MPIK explains. "The reactions of HeH+ with neutral hydrogen and deuterium therefore appear to have been far more important for chemistry in the early Universe than previously assumed." The research has been published in Astronomy & Astrophysics. Related News Scientists Just Admitted Nobody Really Gets Quantum Physics First Quantum Bit Made of Antimatter Captured in Physics Breakthrough Gold Does Something Unexpected When Superheated Past Its Melting Point Solve the daily Crossword
Yahoo
6 hours ago
- Yahoo
Experts reveal potential unintended side effect of Ozempic – and whether we should worry
The use of weight-loss jabs in the UK has skyrocketed, with an estimated 1.5 million people using them. Yet drugs like Ozempic and Wegovy don't just help people lose fat, but potentially muscle too, new research has suggested. A study that tested weight loss jabs on mice found that although muscle mass changes less than expected, muscles still get weaker and tissues like the liver also shrink. Weight-loss injections, also known as GLP-1 receptor agonists, work by mimicking the natural hormone which regulates blood sugar, appetite and digestion. The medications, known as semaglutides, predominantly treat diabetes but are also available on the NHS or via private providers to help adults with a high body mass index (BMI). For example, although Ozempic is used for type 2 diabetes, it is sometimes prescribed off-label as a weight-loss drug. The results of the study, published in the journal Cell Metabolism, revealed Ozempic-induced weight loss decreased muscle mass by about 10 per cent. Most of this lost weight wasn't from skeletal muscles, which surround bones and joints, but instead from other tissues like the liver, which shrank by nearly half. However, because the Ozempic was tested on mice, researchers emphasise that more research is needed to determine whether similar changes to organ size occur in humans and whether those changes come with any risks. 'Loss of mass in metabolically active organs, such as the liver, is expected as part of healthy weight loss,' said Dr Ran Hee Choi, research instructor in nutrition and integrative physiology at the University of Utah college of health, and co-first author on the study. In both mice and humans, weight gain and loss can affect the size of organs like the liver without affecting their function. 'It's unlikely that the observed lean mass loss represents a serious adverse effect,' added Dr Takuya Karasawa, another co-first author on the study. Researchers found some skeletal muscles did shrink by about 6 per cent as the mice lost weight, but not enough to explain the overall muscle loss. However, when someone gains fat, they also tend to gain skeletal muscle. Study authors explain this is because the body needs to work harder to move around. As a result, losing extra fat can lead to a loss of muscle, which will not affect the person's overall quality of life. Researchers also tested the amount of force the mice's muscles exerted and found that some muscle strength decreased as the mice lost weight, even when the size of the muscle stayed roughly the same. This potential loss of strength when taking Ozempic could be a particular concern for adults over the age of 60 who are at a higher risk of muscle loss and reduced mobility. 'The loss of physical function is a strong predictor of not just quality of life but longevity,' added Dr Katsu Funai, professor of nutrition at the University of Utah and the senior author on the study. Dr Funai concluded that further clinical trials of weight loss jabs should check for changes in muscle strength. A spokesperson for Novo Nordisk, which makes Ozempic, said: 'In clinical trial for Wegovy or Ozempic we did not specifically study the medicine's impact on muscle mass. In a sub-study of 140 patients with a BMI of 40 or less, analysis suggested that treatment with Wegovy was accompanied by reductions in both fat and lean body mass, with a greater reduction in fat mass than lean body mass. 'We recommend that any patients experiencing side effects while taking Wegovy or Ozempic contact their healthcare provider.'